RIPK3 and Familial prostate cancer: In contrast, SIRT3, along with SIRT6, can also be considered as hallmarks of poorer prognosis in prostate cancer patients as these SIRTs inhibit necroptosis receptor-interacting protein kinase 3 (RIP3/RIPK3) pathway and immune response, while when knocked down in vitro immune response and necroptosis recovery occurred [69].